Advertisement
ALC vs SYK
Which Stock Would AI Choose? Alcon Inc. (ALC) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- SYK boasts a larger market capitalization of approximately $113 billion compared to ALC's $37 billion, reflecting broader diversification in medical technologies.
- SYK has delivered stronger year-to-date performance at around 16%, outpacing ALC's 6.5% gain amid recent market volatility.
- Recent operational challenges, including a cyber incident for SYK, impacted quarterly results, while ALC benefits from product innovations and research collaborations.
- Both stocks trade near their 52-week lows, with ALC at about $74 and SYK around $295, presenting potential value opportunities in healthcare.
- Price-to-earnings (P/E) ratios are comparable, at 37 for ALC and 35 for SYK, indicating similar valuations relative to earnings.
- Tickeron's AI tools highlight momentum edges for SYK despite headwinds.
Introduction
In the competitive healthcare sector, ALC and SYK represent key players in medical devices and eye care, appealing to growth-oriented investors and traders seeking exposure to innovative treatments and procedures. This comparison evaluates their business models, recent market positioning, and performance drivers in the current environment. With aging populations boosting demand for vision and orthopedic solutions, understanding relative strengths in revenue growth, operational resilience, and sentiment shifts helps inform stock comparison decisions for portfolios focused on long-term healthcare trends.
ALC Overview and Recent Performance
Alcon Inc. (ALC) specializes in eye care, spanning surgical equipment, contact lenses, and pharmaceuticals. In recent market activity, the stock has hovered near its 52-week low of $71.55, trading around $74 with a market cap of $37 billion. Sentiment has been influenced by positive developments like the launch of Clareon TruPlus intraocular lenses and collaborations in vision research, alongside annual general meeting outcomes. Upcoming first-quarter 2026 earnings are anticipated to shed light on revenue growth, which reached $10.4 billion trailing twelve months, supported by an 8.6% quarterly uptick. Broader stability in the vision care segment has tempered volatility compared to peers.
SYK Overview and Recent Performance
Stryker Corporation (SYK) is a diversified medical technology firm focused on orthopaedics, MedSurg, and Neurotechnology products. Shares have traded around $295 near the 52-week low of $294.55, with a substantial $113 billion market cap. Recent weeks saw pressure from a cyber incident disrupting first-quarter 2026 operations, leading to $6.02 billion in revenue (up 2.6% year-over-year) that missed estimates, though full-year guidance of 8-9.5% organic growth was reaffirmed. Net sales resilience and acquisitions like Amplitude Vascular Systems have bolstered investor confidence, contributing to year-to-date gains outpacing the sector.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies and timeframes. Currently featuring 25 bots suited to prevailing market conditions, these showcase win rates averaging around 60% (ranging 51-88%), annualized returns up to 163%, and profit factors from 1.5 to 11.7. Short-term focus prevails with 5-60 minute intervals, employing AI/ML for trend following, dip buying, and multi-agent tactics, often with tight take-profit/stop-loss corridors like 3%/2%. Max drawdowns vary but highlight risk-adjusted edges, appealing to active traders. Explore these bots to align automated strategies with stocks like ALC and SYK in dynamic conditions.
Head-to-Head Comparison
ALC’s niche focus on eye care offers targeted growth via surgical and vision products, contrasting SYK’s broader exposure across orthopaedics and neurotech, enabling scale through mergers and acquisitions (M&A, deals combining companies). SYK drives momentum with higher unit volumes despite cyber risks, while ALC emphasizes steady innovation amid regulatory hurdles in ophthalmology. Valuation trade-offs show similar P/E ratios, but SYK’s larger revenue base provides diversification against sector downturns. Market sentiment favors SYK’s resilience, though ALC’s specialized catalysts could narrow the gap in relative performance.
Tickeron AI Verdict
Tickeron’s AI currently leans toward SYK based on superior year-to-date momentum, reaffirmed growth guidance amid challenges, and expansive market positioning. While ALC shows stability through product advancements, SYK’s trend consistency and scale offer probabilistic advantages in the near term for healthcare-focused strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a StrongBuy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- ALC’s TA Score: 5 bullish, 3 bearish.
- SYK’s TA Score: 5 bullish, 3 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +0.06% price change this week, while SYK (@Medical/Nursing Services) price change was +2.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.49%. For the same industry, the average monthly price growth was +1.13%, and the average quarterly price growth was -15.35%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.39%. For the same industry, the average monthly price growth was +1.95%, and the average quarterly price growth was -16.80%.
Reported Earning Dates
ALC is expected to report earnings on Aug 10, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.49% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-1.39% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ALC | SYK | ALC / SYK | |
| Capitalization | 32.6B | 120B | 27% |
| EBITDA | 2.54B | 6.44B | 39% |
| Gain YTD | -15.176 | -10.933 | 139% |
| P/E Ratio | 40.03 | 36.13 | 111% |
| Revenue | 10.6B | 25.3B | 42% |
| Total Cash | 1.66B | 2.97B | 56% |
| Total Debt | 5.25B | 14.7B | 36% |
ALC | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 64 | |
SMR RATING 1..100 | 89 | 57 | |
PRICE GROWTH RATING 1..100 | 61 | 60 | |
P/E GROWTH RATING 1..100 | 50 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (10) in the Medical Specialties industry is in the same range as ALC (18) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
SYK's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for ALC (100) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew somewhat faster than ALC’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as ALC (89) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
SYK's Price Growth Rating (60) in the Medical Specialties industry is in the same range as ALC (61) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew similarly to ALC’s over the last 12 months.
ALC's P/E Growth Rating (50) in the Hospital Or Nursing Management industry is in the same range as SYK (81) in the Medical Specialties industry. This means that ALC’s stock grew similarly to SYK’s over the last 12 months.
| ALC | SYK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 40% | 3 days ago 50% |
| Stochastic ODDS (%) | 3 days ago 55% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 63% | 3 days ago 60% |
| MACD ODDS (%) | 3 days ago 64% | 3 days ago 75% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 46% |
| Advances ODDS (%) | 3 days ago 58% | 10 days ago 55% |
| Declines ODDS (%) | 12 days ago 56% | 4 days ago 53% |
| BollingerBands ODDS (%) | 7 days ago 58% | 3 days ago 67% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 47% |
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.